Clinical studies in non-small cell lung cancer: The CALGB experience

Cancer Investigation

Volumn 16, Issue 2, 1998, Pages 72-79

  Yokes, Everett E ^a   Green, Mark R ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031944941     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909809039760     Document Type: Article

References (48)

1. Ginsberg R, Yokes EE, Raben A: Non-small cell lung cancer. In: Cancer-Principles and Practice of Oncology. Eds: De Vita Jr YT, Hellman S, Rosenberg SA. 5th Edition, J.B. Lippincott Co., Philadelphia, 858-910, 1997.
2. Haraf DJ, Devine SM, Ihde DC, Yokes EE: The evolving role of systemic therapy in carcinoma of the lung. Semin Oncol 19 (Suppl 11):72-87, 1992.
3. Strauss GM, Langer MP, Elias AD, Skarin AT, Sugarbaker DJ: Multimodality treatment of stage IIIA non-small cell lung carcinoma: A critical review of the literature and strategies for future research. J Clin Oncol 10:829-838, 1992.
4. Yokes EE, Bitran JD: Non-small cell lung cancer: towards the next plateau. Chest 106:659-661, 1994 (editorial).
5. Cormier Y, Bergeron D, La Forge J, Lavandier M, Founder M, Chenard J, Desmeules M: Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer 50:845-849, 1982.
6. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM, Ayoub JI, Wilson KS, Latreille J, Wierzbicki RF, Hill DP: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - Report of a Canadian Multicenter Randomized Trial. J Clin Oncol 6:633-641,1988.
7. Quoix E, Dietemann A, Charbonneau J, et al: La chimiotherapie comportant du cisplatine est-elle utile dans le cancer bronchique non microcellulaire au stade IV? Resultants d'une etude randomisee. Bull Cancer 78:341-346, 1991.
8. Cartei G, Cartel F, Cantone A, Causarano D, Genco G, Tobaldin A, Interlandi G, Giraldi T: Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst 85:794-800, 1993.
9. Grilli R, Oxman AD, Julian JM: Chemotherapy for advanced non-small cell lung cancer: How much benefit is enough? J Clin Oncol 11:1866-1872.
10. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods EL, Bernard JP: Poly chemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet 342:19-21, 1993.
11. Marino P, Pampallona S, Prestoni A, Cantoni A, Inveraizzi F: Chemotherapy versus supportive care in advanced non-small cell lung cancer. Results of a meta-analysis of the literature. Chest 106:861-865, 1994.
12. Stewart LA, Pignon JP, Parmar AKB, Le Chevalier T, Souhami RL, on behalf of the NSCLC Collaborators Group: A meta-analysis using individual patient data from randomised clinical trials of chemotherapy in non-small cell lung cancer: Survival in the supportive care setting. Proc Am Soc Clin Oncol 13, 1994 (abstract).
13. Dillman RO, Seagreen SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF III, Green MR: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 323:940-945, 1990.
14. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991.
15. Le Chevalier T, Arriagada R, Tarayre M, Lacombe-Terrier MJ, Laplanche A, Quoix E, Ruffie P, Martin M, Douillard JY: Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 84:58, 1992.
16. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 8808 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198-205, 1995.
17. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, Kirkpatrick A, Koolen M, Maat B, Nijs A, Renaud A, Rodrigus P, Schuster-Uitterhoeve L, Sculier JP, van Zandwijk N, Bartelink H: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992.
18. Yokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: Rationale and clinical experience in patients with solid tumors. J Clin Oncol 8:911-934, 1990.
19. Yokes EE: Interactions of chemotherapy and radiation. Semin Oncol 20:70-79, 1993.
20. Green MR, Kramar A, Schilsky R, Stoopler M, Zimmer B, Richards F, Skarin A, Anderson JR: Platinum-based combination chemotherapy in advanced non-small cell lung cancer: A randomized phase II trial of the Cancer and Leukemia Group B. Med Pediatr Oncol 18(3):197-202, 1990.
21. Richards F II, Perry DJ, Goutsou M, Modeas C, Muchmore E, Rege V, Chahinian AP, Hirsh V, Poiesz B, Green MR: Chemotherapy with 5-fluorouracil and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the Cancer and Leukemia Group B. Cancer 67:2974-2979, 1991.
22. Citron ML, Modeas C, Propert K, Goutsou M, Green MR: Phase II trial of high-dose 24-hour continuous intravenous 5-fluorouracil for advanced non-small cell lung cancer. A Cancer and Leukemia Group B study. Cancer Invest 10(3):215-219, 1992.
23. Yokes EE, Lyss AP, Herndon JE II, Cooper B, Perry MC, Vinciguerra V, Mason-Coughlin K, Green MR: Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: A randomized phase II study of the cancer and leukemia group B. Ann Oncol 3:727-732, 1992.
24. Lynch Jr. TJ, Kalish LA, Kass F, Strauss G, Elias A, Skarin A, Shulman L, Sugarbaker D, Frei E: Continuous-infusion cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer. Cancer 73:1171-1176, 1994.
25. Kreisman H, Ginsberg S, Propert KJ, Richards F, Graziano S, Green M: Carboplatin or iproplatin in advanced non-small cell lung cancer: A Cancer and Leukemia Group B study. Cancer Treat Rep 71:1049-1052, 1987.
26. Green MR, Kreisman H, Doll DC, Lyss AP, Clamon GH, Goutsou M, Perry MC, Propert KJ: Carboplatin in non-small cell lung cancer: An update on the Cancer and Leukemia Group B experience. Semin Oncol 19(1 Suppl 2):44-49, 1992.
27. Lyss AP, Perry MC, Goutsou M, Propert K, Herndon JE II, Mason-Coughlin K, Green MR: Intensive etoposide and carboplatin chemotherapy for advanced non-small cell lung cancer. A phase II trial of the Cancer and Leukemia Group B. Am J Clin Oncol 15(5):399-404, 1992.
28. Doll DC, Goutsou M, Grazianos, et al: Carboplatin and vinblastine in advanced non-small cell lung cancer: A phase II study. Cancer Chemother Pharmacol 29:71-74, 1991.
29. Graziano SL, Herndon JE II, Richards F II, DiFino S, Modeas C, Duggan DB, Green MR: A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer: A Cancer and Leukemia Group B study. Cancer 72:62-68, 1993.
30. Graziano SL, Valone FH, Herndon JE II, Crawford J, Richards F II, Rege VB, Clamon G, Green MR: A randomized phase li study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: A Cancer and Leukemia Group B study. Lung Cancer 14:315-329, 1996.
31. Kosty MP, Fleishman SB, Herndon JE II, et al: Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small cell lung cancer: A randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 12:1113-1120, 1994.
32. Chlebowski RT, Bulcavage I, Grosvenor M, et al: Hydrazine sulfate influence on nutritional status and survival in non-small cell lung cancer. J Clin Oncol 8:9-15, 1990.
33. Loprinzi CL, Goldberg RM, Su JQ, et al: Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 12:1126-1129, 1994.
34. Herbert V: Three stakes in hydrazine sulfate's heart, but questionable cancer remedies, like vampires, always rise again. J Clin Oncol 12:1107-1108, 1994 (editorial).
35. Masters GA, Hoffman PC, Drinkard LC, Watson S, Samuels S, Golomb HM, and Yokes EE: Preliminary report on a phase I study of ifosfamide and vinorelbine (Navelbine) in advanced non-small cell lung cancer. Semin Oncol 23 (Suppl 5): 11-18, 1996.
36. Hoffman PC, Masters GA, Drinkard LC, Krauss SA, Samuels B, Golomb H, Yokes EE: Ifosfamide plus paclitaxel in advanced non-small cell lung cancer: A phase I study. Ann Oncol 7:314-316, 1996.
37. Seagren SL, Herndon JE, Backer JR, et al: Alternating irradiation and chemotherapy in stage III A and B nonsmall cell lung cancer: Report of a Cancer and Leukemia Group B Phase II Study 8636. Int J Radiat Oncol Biol Phys 29:1085-1088, 1994.
38. Kreisman H, Lisbona A, Olson L, Propert KJ, Modeas C, Dillman RO, Seagren SL, Green MR: Effect of radiologic stage IQ sub-stage on nonsurgical therapy of non-small cell lung cancer. Cancer 72:1588-1596, 1993.
39. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR: Improved survival in stage III non-small-cell lung cancer: Seven year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 88:1210-1215, 1996.
40. Clamon G, Herndon J, Eaton W, et al: A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: A phase II trial of Cancer and Leukemia Group B. Cancer Invest 12(3):273-281, 1994.
41. Lilenbaum RC, Green MR: Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol 11:1391-1402, 1993.
42. Yokes EE: Integration of vinorelbine into current chemotherapy strategies for advanced non-small cell lung cancer. Oncology 9:565-577, 1995.
43. Yokes EE, Haraf DJ, Masters GA, Hoffman PC, Drinkard LC, Ferguson M, Olak J, Watson S, Golomb HM: Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: A phase I study. Semin Oncol 23 (Suppl 5):48-52, 1996.
44. Meyer JT, Spencer SA, Jennelle RLS, Kim RY, Meredith RF, Wheeler RH, Robert F: Phase I study of concurrent taxol/cisplatin with thoracic radiation (TR) in locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 15:372, 1996 (abstract #1104).
45. Strauss GM, Herndon JE, Sherman DD, Mathisen DJ, Carey RW, Choi NC, Rege VB, Modeas C, Green MR: Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: Report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 10:1237-1244, 1992.
46. Sugarbaker D, Herndon J, Kohman L, et al: Patterns of recurrence in CALGB 8935, a tri-modality trial for IIIA (N2) non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 13:348, 1994 (abstract #1165).
47. Roth JA, Fossella F, Komaki R, et al: A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable IIIA non-small-cell lung cancer. J Natl Cancer Inst 86:673-680, 1994.
48. Rosell R, Gomez-Codina J, Camps C, et al: A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330:153-158, 1994.